Palisade bio announces closing of $2 million registered direct offering priced at market under nasdaq rules

Carlsbad, ca, sept. 11, 2023 (globe newswire) -- palisade bio, inc. (nasdaq: pali), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (gi) complications, is announcing today that it has closed its previously announced registered direct offering with institutional investors for the purchase of 2,339,398 shares of common stock for gross proceeds of $1,965,094.32.
PALI Ratings Summary
PALI Quant Ranking